Tumour‐released pro‐inflammatory cytokines, such as tumour necrosis factor alpha (TNF‐α), interferon gamma (INF‐γ), interleukin 6 (IL‐6), induce degradation of myofibril proteins, especially myosin heavy chain (MyHC), through NF‐κB (nuclear factor ‘kappa‐light‐chain‐enhancer’ of activated B‐cells)‐MuRF1 (muscle RING‐finger protein‐1) ubiquitin‐proteasome pathway [9]. Here, IL6 is linked to neoplasm.